Illumina (NASDAQ:ILMN - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results after the market closes on Thursday, July 31st. Analysts expect Illumina to post earnings of $1.02 per share and revenue of $1.12 billion for the quarter. Illumina has set its FY 2025 guidance at 4.200-4.300 EPS.
Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, topping analysts' consensus estimates of $0.96 by $0.01. Illumina had a negative net margin of 22.25% and a positive return on equity of 25.54%. The business had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.03 billion. During the same period last year, the firm earned $0.98 earnings per share. Illumina's revenue for the quarter was down 1.4% compared to the same quarter last year. On average, analysts expect Illumina to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.
Illumina Price Performance
ILMN stock traded up $1.66 during mid-day trading on Friday, hitting $109.30. The stock had a trading volume of 1,937,527 shares, compared to its average volume of 2,248,812. The company has a current ratio of 1.86, a quick ratio of 1.48 and a debt-to-equity ratio of 0.63. Illumina has a 52 week low of $68.70 and a 52 week high of $156.66. The firm has a market capitalization of $17.30 billion, a P/E ratio of -18.01, a P/E/G ratio of 2.10 and a beta of 1.36. The firm has a fifty day simple moving average of $91.50 and a 200 day simple moving average of $94.09.
Wall Street Analyst Weigh In
Several research firms have commented on ILMN. Stephens reissued an "overweight" rating and issued a $105.00 target price on shares of Illumina in a report on Tuesday, May 20th. Citigroup lowered shares of Illumina from a "hold" rating to a "strong sell" rating and decreased their price target for the company from $85.00 to $80.00 in a report on Wednesday, July 9th. JPMorgan Chase & Co. decreased their price target on shares of Illumina from $120.00 to $85.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Barclays reaffirmed an "underweight" rating and set a $85.00 price target (up from $77.00) on shares of Illumina in a report on Tuesday, June 24th. Finally, Morgan Stanley decreased their price target on shares of Illumina from $136.00 to $100.00 and set an "equal weight" rating on the stock in a report on Monday, May 12th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $125.11.
Get Our Latest Research Report on ILMN
Insider Activity
In other news, CFO Ankur Dhingra purchased 6,100 shares of the company's stock in a transaction dated Monday, May 12th. The shares were purchased at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the transaction, the chief financial officer owned 24,906 shares of the company's stock, valued at approximately $2,022,616.26. This trade represents a 32.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 2.60% of the company's stock.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Illumina stock. Empowered Funds LLC increased its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 113.7% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,284 shares of the life sciences company's stock after acquiring an additional 4,940 shares during the quarter. Empowered Funds LLC's holdings in Illumina were worth $737,000 at the end of the most recent reporting period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.
Illumina Company Profile
(
Get Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
See Also

Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.